Post-Marketing Surveillance of Kadcyla in Breast Cancer
Post-Marketing Surveillance of Kadcyla in Breast Cancer
This is a phase IV, prospective, multicenter, non-interventional study (regulatory post-marketing surveillance) in approximately 500 patients who are to receive Kadcyla (trastuzumab emtansine). Patients administered Kadcyla infusion at physician's discretion will be registered for this surveillance in Korea. Patients will be asked to provide informed consent; data will be collected by electronic Case Report Forms for approximately 8 years.
Inclusion Criteria:
Exclusion Criteria:
Daegu, South Korea
Gyeongsangnam-do, 50612, South Korea
Jeollabuk-do, 561-712, South Korea
Jeollanam-do, 58128, South Korea
Jeonlabuk-do, 54538, South Korea
Kyonggi-do, 411-719, South Korea
Seoul, 01812, South Korea